47 results
424B3
HUMA
Humacyte, Inc.
4 Oct 24
Prospectus supplement
4:01pm
an applicable income tax treaty) on the gain derived from the sale, which gain may be offset by U.S.-source capital losses for the year.
In addition, if our
8-K
EX-99.2
HUMA
Humacyte, Inc.
13 Aug 24
Results of Operations and Financial Condition
7:04am
months ended June 30, 2023. The slight decreases during 2024, resulted primarily from a decrease in non-cash stock compensation expense, partially offset
424B5
cc2oq
1 Mar 24
Prospectus supplement for primary offering
4:05pm
424B5
06q78j uazi29ov
29 Feb 24
Prospectus supplement for primary offering
4:11pm
8-K
EX-99.1
mcw6e54e
9 Nov 23
Humacyte Third Quarter 2023 Financial Results and Business Update
4:07pm
8-K
EX-99.1
vl1jkn
10 Nov 22
Humacyte Third Quarter 2022 Financial Results and Business Update
7:04am
424B3
3ar54
12 Aug 22
Prospectus supplement
9:11am
8-K
EX-99.1
zdjg8
12 Aug 22
Humacyte Second Quarter 2022 Financial Results and Business Update
7:04am
424B3
lfh6sl
13 May 22
Prospectus supplement
9:14am